Abstract
Carbonic anhydrase IX (hCA IX) is a membrane-associated glycoprotein that is observed in many tumor tissues and is strongly overexpressed by hypoxia conditions. Hypoxia is a clinically important tumor parameter and this enzyme can play an important role as a potential marker of hypoxic tumor and as a therapeutic target too. In the last years, Carbonic Anhydrase IX Inhibitors which possess fluorescent probe were largely used for visualize hypoxic tumor cell lines and for understanding the biological roles of hCA IX in acidification of the external matrix. Here we resume the developement pathways of such compounds from the design to the final biological evaluation. Furthermore, spin-labeled CAIs were included to have a complete overview of the potenciality of this enzyme as marker of hypoxic tumors.
Keywords: Carbonic anhydrase inhibitors, hCA IX, hypoxic tumor, extracellular pH, fluorescent sulfonamide, spin-labeled sulfonamide
Current Pharmaceutical Design
Title: Fluorescence- and Spin-Labeled Carbonic Anhydrase Inhibitors
Volume: 14 Issue: 7
Author(s): Alessandro Cecchi and Claudiu T. Supuran
Affiliation:
Keywords: Carbonic anhydrase inhibitors, hCA IX, hypoxic tumor, extracellular pH, fluorescent sulfonamide, spin-labeled sulfonamide
Abstract: Carbonic anhydrase IX (hCA IX) is a membrane-associated glycoprotein that is observed in many tumor tissues and is strongly overexpressed by hypoxia conditions. Hypoxia is a clinically important tumor parameter and this enzyme can play an important role as a potential marker of hypoxic tumor and as a therapeutic target too. In the last years, Carbonic Anhydrase IX Inhibitors which possess fluorescent probe were largely used for visualize hypoxic tumor cell lines and for understanding the biological roles of hCA IX in acidification of the external matrix. Here we resume the developement pathways of such compounds from the design to the final biological evaluation. Furthermore, spin-labeled CAIs were included to have a complete overview of the potenciality of this enzyme as marker of hypoxic tumors.
Export Options
About this article
Cite this article as:
Cecchi Alessandro and Supuran T. Claudiu, Fluorescence- and Spin-Labeled Carbonic Anhydrase Inhibitors, Current Pharmaceutical Design 2008; 14 (7) . https://dx.doi.org/10.2174/138161208783877839
DOI https://dx.doi.org/10.2174/138161208783877839 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imiquimod
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry Baicalin-induced Cytotoxicity and Apoptosis in Multidrug-resistant MC3/5FU Mucoepidermoid Carcinoma Cell Line
Letters in Drug Design & Discovery Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
Clinical Cancer Drugs Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Mouse Mutants of Relaxin, Insulin-Like 3 Peptide and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design Cytotoxicity and Toxicological Studies of <i>Artocarpus altilis</i> Extracts, Inducing Apoptosis and Cell Cycle Arrest via <i>CASPASE-3</i> and <i>CASPASE-8</i> Pathways against Human Breast MCF-7 Cells
Combinatorial Chemistry & High Throughput Screening Transposon-Based Engineering of Clinical-Grade T Cells for Cancer Therapy
Current Drug Therapy Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets A Systematic in-silico Analysis of Helicobacter pylori Pathogenic Islands for Identification of Novel Drug Target Candidates
Current Genomics